MDNA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (20 Mar 2024 @ 04:00):

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases...

Stats
今日成交量	1.19M
平均成交量	0.00
市值	10.93M
EPS	$0 ( 2024-02-05 )
下一个收益日期	( $0 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.740
ATR14	$0.0420 (11.51%)

音量相关性

長: -0.14 (neutral)

短: 0.63 (weak)

Signal:(57.847) Neutral

Medicenna Therapeutics 相关性

10 最正相关
RTPY	0.847
CRCT	0.843
SPCB	0.84
EMBCV	0.838
SQQQ	0.834
DISH	0.831
DSWL	0.828
SGML	0.825
TC	0.824
BSGM	0.818

10 最负相关
INZY	-0.888
VSMV	-0.882
CGNT	-0.881
PPH	-0.872
BLDR	-0.872
PFM	-0.87
FTCS	-0.869
DGRW	-0.869
USMC	-0.867
PATK	-0.867

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Medicenna Therapeutics 相关性 - 货币/商品

-0.64
( weak negative )

0.00
( neutral )

-0.49
( neutral )

0.30
( neutral )

0.47
( neutral )

Medicenna Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0.0239

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0.0239

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.420

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Medicenna Therapeutics

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.